ClinicalTrials.gg
CompletedNCT00359463Updated Nov 13, 2017

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

A Phase 1 interventional study of eltrombopag in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Apr 2006, registered Jul 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing eltrombopag in Purpura — none open to participants now, none under way, none of them phase 3. eltrombopag · Purpura.

Enrollment
10th of 11
33 · median 82
Started
2006
with 3 others
Phase 1
4 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
9 of 11
GlaxoSmithKline

Among the 11 studies testing eltrombopag in Purpura, this one is the 10th largest by enrollment, is one of 4 that started in 2006, is one of 4 in phase 1, and was the 3rd registered.

Purpura

45 studies on the registry are indexed under Purpura; 4 are open to participants now.

Browse Purpura studies →

Open to participants now

None of the 11 studies testing eltrombopag in Purpura is open now. The open studies under Purpura, anywhere →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 4 Purpura studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eltrombopag in Purpura as a file.
02

Study summary

The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.

03

Conditions studied

  • Purpura, Thrombocytopaenic, Idiopathic

Keywords

  • hepatitis C-associated thrombocytopenia
  • chemotherapy induced thrombocytopenia
  • thrombocytopenia
  • hepatic impairment
  • chronic immune thrombocytopenia purpura
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy or have liver impairment
  • Females(the following requirement applies only if able to have children): agree to doctor approved methods, or partner has had a vasectomy.
  • (BMI-within acceptable range)
  • Negative drug, alcohol, and tests

Exclusion criteria

Exclusion criteria:

  • Taking a medication or therapy not approved by the study doctor
  • Rapidly changing liver function
  • Kidneys not working well
  • Drug or alcohol abuse within past 6 months
  • Used an drug in the past 30 days
  • Females that are pregnant or nursing
  • Have active or C
  • History of blood disorders
  • History of various heart conditions (as noted by study doctor)
  • Blood clotting problems or blood abnormalities
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    Healthy subjects

    Subjects will receive a single 50 mg oral dose of eltrombopag.

    Drug: eltrombopag

  • Experimental
    Subjects with hepatic impairment

    Subjects with mild, moderate or severe hepatic impairment will receive a single 50 mg oral dose of eltrombopag.

    Drug: eltrombopag

Interventions

  • Subjects will be administered a single oral dose of 50 mg eltrombopag.

06

What researchers measure

Primary outcomes

  1. Plasma levels and protein binding of eltrombopag

    Time frame: Day 1 to Day 6

Secondary outcomes

  1. Safety will be monitored by: - clinical lab tests - vital signs - electrocardiograms - monitoring for adverse events - physical exams - eye exams

    Time frame: throughout the study

07

Study locations

5 sites
  • GSK Investigational Site
    Gainesville, Florida 32608, United States
  • GSK Investigational Site
    Orlando, Florida 32809, United States
  • GSK Investigational Site
    Randwick, Sydney, New South Wales 2031, Australia
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
  • GSK Investigational Site
    Christchurch, 8011, New Zealand
08

References and documents

Publications

  • Bauman JW, Vincent CT, Peng B, Wire MB, Williams DD, Park JW. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol. 2011 May;51(5):739-50. doi: 10.1177/0091270010372106. Epub 2010 Jul 27. PubMed 20663991 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2006 to primary completion in Mar 2007, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2006
First posted
Aug 2, 2006
StartActual
Apr 18, 2006
Primary completionActual
Mar 7, 2007
CompletionActual
Mar 7, 2007
Last update
Nov 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00359463
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 2, 2006
Start date
Apr 18, 2006
Primary completion
Mar 7, 2007
Completion
Mar 7, 2007
Last update
Nov 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion